{"prompt": "['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'Denture Retention and Stability Assessment', 'OST (Edentulous) Examination', 'Urine Pregnancy Testing (for females of child-bearing potential only)', 'Subject Eligibility', '8.1.1', 'Informed Consent', 'The investigator, or designee, must obtain informed consent from each subject participating in', 'this study after adequate explanation of the aims, methods, objectives, and potential hazards of', 'the study. Two copies of the informed consent form (ICF) will be signed and dated by the', 'subject, the subject will retain one copy and the other will be kept at site.', 'The investigator, or designee, must also explain to the subjects that they are completely free to', 'refuse to enter the study or to withdraw from it at any time. Appropriate forms for documenting', 'a signed and dated consent will be provided by either the investigator or by GSK CH.', 'The investigator, or designee, should sign and date each copy of the ICF to confirm that the', 'consent process was completed correctly after the subject has signed.', 'The time the subject signed the informed consent form will also be captured on the Informed', 'Consent Form as this is the point at which all Adverse Events will be captured from. The date', 'and time of consent will be transcribed to the CRF.', \"If, during a subject's participation in the study, any new information becomes available that\", \"may affect the subject's willingness to participate in the study, each ongoing subject should\", 'receive a copy of this new information and be re-consented into the study. Each subject should', 'be provided with a copy of the signed and dated amended consent form. The date of re-consent', 'will be recorded on the CRF.', 'After signing the ICF, subjects will undergo the screening assessments to confirm that they', 'meet all the inclusion criteria and none of the exclusion criteria. If the subject is confirmed', 'eligible by the investigator (or designee) to participate in the study the subject is considered', 'enrolled in the study.', 'e-Consent is a tool that assists in the consent process by using multimedia components delivered', 'by an electronic system (e.g. IPad/tablet). The multimedia components consist of video, audio,', 'knowledge review, dictionary and electronic signature.', 'The site staff can use the system to consent the subject with the benefit of helping the subject', 'understand the research they are taking part in and to control the consent process.', 'The system will allow for a copy of the consent to be printed and given to the subject and for', 'consent documents to be retained by the site in PDF format.', 'A GSK CH approved vendor will be used to provide the system and training and help desk will', 'be provided as needed.', 'If the country and/or site does not have approval to use the e-Consent system, or the subject', 'does not want to use the e-Consent system, then the conventional paper process will be followed.', 'It is possible to use the e-Consent system to educate the subject while using paper to obtain', 'signatures.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 28 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', '8.1.2', 'Demographics', 'The following demographic information will be recorded in the CRF: year of birth, gender,', 'ethnicity and race. Ethnicity and race of subjects will be recorded in accordance with FDA', 'Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials, 2005.', '8.1.3', 'Inclusion/Exclusion Criteria', 'Inclusion and exclusion criteria information will be documented in the CRF. The well-made', 'assessment of dentures, denture retention and stability assessment, denture bearing tissue score,', 'MSA and OST examination should be performed by suitably qualified personnel with expertise', 'in prosthodontics.', '8.1.4', 'Medical History and Prior Medication/Treatment', 'Details of relevant medical and surgical history (in the last year), including allergies or drug', 'sensitivity, will be documented in the CRF.', 'Prior medications/treatments, including prescription and non-prescription drugs, dietary', 'supplements and herbal remedies, taken in the last 7 days and prior to signing the informed', 'consent form, will be documented in the CRF.', '8.1.5', 'Dental History', 'The Investigator, or medically qualified designee, will take a dental history from each subject.', 'Dental history will include information of all prostheses in the mouth, maxillary and', 'mandibulary, as well as information regarding the age of the dentures, how long the subject has', 'worn dentures, the prosthetic teeth material and whether the subject has used denture adhesives', 'in the past (including the reason for abstaining from adhesive use and how long since abstaining', 'from adhesive use).', '8.1.6', 'Subject Eligibility', 'The investigator and/or medically qualified designee will review inclusion/exclusion criteria,', 'medical history, prior medications to confirm subject eligibility to participate in the clinical trial.', 'This will be documented in the CRF.', 'To prepare for study participation, subjects will be instructed in the Lifestyle Guidelines and', 'any Concomitant Medication/Treatment(s) requirements of the protocol.', '8.2', 'Study Period', 'Remind subject to inform the site if they experience any untoward medical occurrence or use', 'any medications while enrolled in the study.', '8.2.1', 'Visit 1/Day 1 (Baseline)', 'Following screening, enrolled subjects will undergo, in the following order (wherever possible),', 'and findings documented in the CRF:', 'Mucosal Score Assessment.', 'Subjects complete the Gum Comfort questionnaire.', 'Subjects complete the OHIP-Edent questionnaire.', 'Subjects complete the GOHAI questionnaire.', 'Randomization of subject to treatment group.', 'Dispense subject diaries to all subjects.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 29 of 65']\n\n###\n\n", "completion": "END"}